These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2169780)

  • 1. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group.
    Smith IE
    Eur J Cancer; 1990; 26 Suppl 1():S19-23. PubMed ID: 2169780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group.
    Soukop M
    Eur J Cancer; 1990; 26 Suppl 1():S15-9. PubMed ID: 2169779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
    Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
    Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group.
    Chevallier B
    Eur J Cancer; 1990; 26 Suppl 1():S33-6. PubMed ID: 2169784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. The Granisetron Study Group.
    Marty M
    Eur J Cancer; 1990; 26 Suppl 1():S28-32. PubMed ID: 2169783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
    Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
    Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
    Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
    Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis.
    Cupissol DR; Serrou B; Caubel M
    Eur J Cancer; 1990; 26 Suppl 1():S23-7. PubMed ID: 2169782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group.
    Smith IE
    J Cancer Res Clin Oncol; 1993; 119(6):350-4. PubMed ID: 8383688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy.
    Tabona MV
    Eur J Cancer; 1990; 26 Suppl 1():S37-44. PubMed ID: 2169785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
    Aksoylar S; Akman SA; Ozgenç F; Kansoy S
    Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
    Sigsgaard T; Herrstedt J; Andersen LJ; Havsteen H; Langer SW; Kjaerbøl AG; Lund H; Kjaer M; Dombernowsky P
    Br J Cancer; 1999 May; 80(3-4):412-8. PubMed ID: 10408847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [BRL 43694A--a 5-hydroxytryptamine receptor blocker as an antiemetic in cytostatic therapy].
    Joss R; Rohrbach D; Buser K; Pirovino M; Karde C; Brunner K
    Schweiz Med Wochenschr; 1989 Jun; 119(23):831-4. PubMed ID: 2549616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy.
    Carmichael J; Harris AL
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):123-8. PubMed ID: 14634790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of the antiemetic effectiveness of granisetron and alizapride plus dexamethasone in cytostatic therapy].
    Bremer K; Uhlenbusch R
    Dtsch Med Wochenschr; 1991 Nov; 116(48):1817-23. PubMed ID: 1659980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy.
    Hesketh PJ; Crews JR; Cohen R; Blackburn LM; Friedman CJ
    Cancer J; 2000; 6(3):157-61. PubMed ID: 10882331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
    Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
    Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granisetron, a selective 5-HT3 receptor antagonist, for the prevention of radiation induced emesis during total body irradiation.
    Hunter AE; Prentice HG; Pothecary K; Coumar A; Collis C; Upward J; Murdoch R; Gandhi L; Hamon M; Butler M
    Bone Marrow Transplant; 1991 Jun; 7(6):439-41. PubMed ID: 1651794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.